These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 21944793)

  • 41. Estrogen as therapy for breast cancer.
    Ingle JN
    Breast Cancer Res; 2002; 4(4):133-6. PubMed ID: 12100736
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cost effectiveness of letrozole versus anastrozole in postmenopausal women with HR+ early-stage breast cancer.
    Lipsitz M; Delea TE; Guo A
    Curr Med Res Opin; 2010 Oct; 26(10):2315-28. PubMed ID: 20731528
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Letrozole in advanced breast cancer: the PO25 trial.
    Mouridsen HT
    Breast Cancer Res Treat; 2007; 105 Suppl 1(Suppl 1):19-29. PubMed ID: 17333340
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Preclinical and clinical experience with fulvestrant (Faslodex) in postmenopausal women with hormone receptor-positive advanced breast cancer.
    Bundred N
    Cancer Invest; 2005; 23(2):173-81. PubMed ID: 15813510
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial.
    Boccardo F; Rubagotti A; Guglielmini P; Fini A; Paladini G; Mesiti M; Rinaldini M; Scali S; Porpiglia M; Benedetto C; Restuccia N; Buzzi F; Franchi R; Massidda B; Distante V; Amadori D; Sismondi P
    Ann Oncol; 2006 Jun; 17 Suppl 7():vii10-4. PubMed ID: 16760270
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.
    Robertson JFR; Bondarenko IM; Trishkina E; Dvorkin M; Panasci L; Manikhas A; Shparyk Y; Cardona-Huerta S; Cheung KL; Philco-Salas MJ; Ruiz-Borrego M; Shao Z; Noguchi S; Rowbottom J; Stuart M; Grinsted LM; Fazal M; Ellis MJ
    Lancet; 2016 Dec; 388(10063):2997-3005. PubMed ID: 27908454
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In situ aromatase expression in primary tumor is associated with estrogen receptor expression but is not predictive of response to endocrine therapy in advanced breast cancer.
    Lykkesfeldt AE; Henriksen KL; Rasmussen BB; Sasano H; Evans DB; Møller S; Ejlertsen B; Mouridsen HT
    BMC Cancer; 2009 Jun; 9():185. PubMed ID: 19531212
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial.
    Smith IE; Dowsett M; Ebbs SR; Dixon JM; Skene A; Blohmer JU; Ashley SE; Francis S; Boeddinghaus I; Walsh G;
    J Clin Oncol; 2005 Aug; 23(22):5108-16. PubMed ID: 15998903
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Lessons from the use of aromatase inhibitors in the neoadjuvant setting.
    Dixon JM; Love CD; Renshaw L; Bellamy C; Cameron DA; Miller WR; Leonard RC
    Endocr Relat Cancer; 1999 Jun; 6(2):227-30. PubMed ID: 10731113
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Letrozole vs. tamoxifen as neoadjuvant therapy for postmenopausal patients with hormone-dependent locally-advanced breast cancer].
    Novoa Vargas A; Font López KC; Amador DD
    Ginecol Obstet Mex; 2011 Sep; 79(9):553-7. PubMed ID: 21966856
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The use of early adjuvant aromatase inhibitor therapy: contributions from the BIG 1-98 letrozole trial.
    Forbes JF
    Semin Oncol; 2006 Apr; 33(2 Suppl 7):S2-7. PubMed ID: 16730270
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.
    De Placido S; Gallo C; De Laurentiis M; Bisagni G; Arpino G; Sarobba MG; Riccardi F; Russo A; Del Mastro L; Cogoni AA; Cognetti F; Gori S; Foglietta J; Frassoldati A; Amoroso D; Laudadio L; Moscetti L; Montemurro F; Verusio C; Bernardo A; Lorusso V; Gravina A; Moretti G; Lauria R; Lai A; Mocerino C; Rizzo S; Nuzzo F; Carlini P; Perrone F;
    Lancet Oncol; 2018 Apr; 19(4):474-485. PubMed ID: 29482983
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial.
    Ewertz M; Gray KP; Regan MM; Ejlertsen B; Price KN; Thürlimann B; Bonnefoi H; Forbes JF; Paridaens RJ; Rabaglio M; Gelber RD; Colleoni M; Láng I; Smith IE; Coates AS; Goldhirsch A; Mouridsen HT
    J Clin Oncol; 2012 Nov; 30(32):3967-75. PubMed ID: 23045588
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial.
    Crivellari D; Sun Z; Coates AS; Price KN; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens RJ; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Gladieff L; Rabaglio M; Smith IE; Chirgwin JH; Goldhirsch A
    J Clin Oncol; 2008 Apr; 26(12):1972-9. PubMed ID: 18332471
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Longitudinal trends in utilization of endocrine therapies for breast cancer: an international comparison.
    Kelly E; Lu CY; Albertini S; Vitry A
    J Clin Pharm Ther; 2015 Feb; 40(1):76-82. PubMed ID: 25367863
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Adjuvant hormone therapy for breast cancer: alternatives to tamoxifen.
    Prescrire Int; 2005 Jun; 14(77):108-10. PubMed ID: 15984106
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results.
    Nabholtz JM; Bonneterre J; Buzdar A; Robertson JF; Thürlimann B
    Eur J Cancer; 2003 Aug; 39(12):1684-9. PubMed ID: 12888362
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Healthcare professionals' preferences for surgery or primary endocrine therapy to treat older women with operable breast cancer.
    Morgan JL; Collins K; Robinson TG; Cheung KL; Audisio R; Reed MW; Wyld L
    Eur J Surg Oncol; 2015 Sep; 41(9):1234-42. PubMed ID: 26108734
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Letrozole versus tamoxifen in the treatment of advanced breast cancer and as neoadjuvant therapy.
    Smith IE
    J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):289-93. PubMed ID: 14623523
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy of first-line letrozole versus tamoxifen as a function of age in postmenopausal women with advanced breast cancer.
    Mouridsen H; Chaudri-Ross HA
    Oncologist; 2004; 9(5):497-506. PubMed ID: 15477634
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.